CNS Pharmaceuticals, Inc. insider trading

Every open-market purchase and sale by CNS Pharmaceuticals, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $44,009 2 trades by 2 insiders 3 months later: median +14.6% (+9.8% vs S&P 500) Insider sales, 5 years $0 0 trades by 0 insiders

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

CNS Pharmaceuticals, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following CNS Pharmaceuticals, Inc.’s insiders pay?

From August 25, 2020 to August 18, 2026, 4 insiders reported 7 open-market purchases and 0 sales not made under a pre-set plan in CNS Pharmaceuticals, Inc. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on May 21, 2026 into $8,693 by November 2, 2026, −26.8% a year. It held shares 100% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $10,237 (+5.4% a year), and held throughout $10,237 (+5.4%).

Copying CNS Pharmaceuticals, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by CNS Pharmaceuticals, Inc.'s insiders from May 21, 2026, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 100% of the time.

CNS Pharmaceuticals, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	12 months after their sales	Latest report
Downs Christopher	Chief Financial Officer	3	—	—	—	February 6, 2024
Climaco John M	Chief Executive Officer	2	—	—	—	February 6, 2024
Charles Faith L.	Director	1	—	—	—	May 20, 2026
Fisher Michal	Director	1	—	—	—	August 18, 2026

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to CNS Pharmaceuticals, Inc. · Funds · Politicians